Dr. Thakker earned her PhD in Pharmaceutical Chemistry at the University of Kansas working under Dr. Higuchi. She worked at US Pharmacopeia for 12 years where she specialized in the development and validation of dissolution methods in the Drug Research and Testing Laboratory. Subsequently, Dr. Thakker held leadership positions at Sphinx Pharmaceuticals and BioAnalytika Laboratories. In 1994, Dr. Thakker exploited her years of experience evaluating drug product performance and leading analytical organizations to launch Analytical Solutions, Inc. (later to become Tergus Pharma) with a mission to provide quality analytical services to the pharmaceutical industry. With the emergence of newer, alternative dosage forms over the past 10 years, she has surfaced as a well-recognized global leader in the development of topical drug products, providing expertise in the development and validation of performance tests used to evaluate the transport of drugs across skin and other membranes (e.g., buccal, sublingual, vaginal, rectal). Working with compendial and regulatory organizations, Dr. Thakker continues to strive towards improving public standards for topical and other dosage forms.
Vijendra NALAMOTHU, Ph.D – Chief Executive Officer
Dr. NALAMOTHU earned his doctoral degree in Pharmaceutics from University of the Sciences’ Philadelphia College of Pharmacy working under Dr. Joseph Schwartz and Dr. Rod Wigent. Prior to Tergus, he was employed with Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, Inc., as the Global Head of Dermatology R&D. He spearheaded the development of specialty branded dermatological products from concept to commercialization including various human clinical trials in US, Europe and India. In addition to North American branded products for Promius, he also developed branded dermatology products for various other countries wherein Dr. Reddy’s markets products for various skin disorders. His interests include novel dosage form design and development of topical drug products, developing new disease models in animals, designing proof of concept studies in humans, animal toxicology studies, human clinical trials, process scale-up and manufacturing. Prior to joining Promius, he served as the Head of Early Compound Assessment group for Sanofi-aventis’ Worldwide Dermatology (Dermik). During his tenure at Dermik’s formulation and early compound assessment groups, Vijendra’s efforts focused on both known molecules and new chemical entities.
Vijendra is able to draw from an exceptional educational background that combined scientific study with pragmatic, hands-on experience solving R&D challenges. He has co/authored numerous publications and has patents for few of his inventions. He has presented his research findings in various international meetings. He is an invited speaker at various meetings and serves as a member of Society for Investigative Dermatology, American Association of Pharmaceutical Sciences and Controlled Release Society. Dr. Nalamothu also serves on the board of few Pharmaceutical and Technology companies and is a member of several pharmaceutical research focus and discussion groups.